2025-09-25 - Analysis Report
Okay, here's a report analyzing Eli Lilly (LLY) based on the data you provided.

## Eli Lilly (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO):**

*   **Cumulative Return (LLY):** 149.96%
*   **Cumulative Return (VOO):** 69.58%
*   **Absolute Spread:** 149.96 - 69.58 = 80.38%
*   **Spread Range:** Max 311.6, Min -27.3
*   **Current Spread:** 121.5
*   **Relative Spread:** 43.9

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO), with a substantial cumulative return difference of 80.38%. The current spread of 121.5 is positioned at the 43.9th percentile of its historical range, indicating that while LLY is outperforming, it's not at its historical peak relative to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2015-2017  | 2.0%  | 85.5% | -23.0% | -0.0 | 75.7   |
| 2016-2018  | 28.0% | 79.8% | 10.0%  | -0.0 | 103.7  |
| 2017-2019  | 34.0% | 79.8% | 8.0%   | -0.2 | 117.8  |
| 2018-2020  | 34.0% | 85.4% | 22.0%  | 0.1  | 151.3  |
| 2019-2021  | 68.0% | 86.4% | 39.0%  | 0.8  | 247.5  |
| 2020-2022  | 50.0% | 86.4% | 54.0%  | 0.4  | 327.8  |
| 2021-2023  | 74.0% | 86.4% | 63.0%  | 0.2  | 522.3  |
| 2022-2024  | 99.0% | 83.5% | 75.0%  | 0.2  | 691.8  |
| 2023-2025  | 74.0% | 99.3% | 34.0%  | 0.2  | 666.1  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR shows strong growth, especially in recent periods (2022-2024).
*   **MDD (Maximum Drawdown):** High MDD values suggest significant volatility.
*   **Alpha:** Consistently positive Alpha values indicate LLY is generating returns above what would be expected based on its Beta (market risk).  Alpha has been exceptionally strong in recent years.
*   **Beta:**  Beta values are generally low, indicating lower sensitivity to overall market movements.
*   **Cap (Market Capitalization):** Market Cap shows substantial growth over time.

**2. Recent Stock Price Movement:**

*   **Current Price:** 743.35
*   **Last Market Close:** Price: 743.34, Previous Close: 746.98, Change: -0.49
*   **5-Day Moving Average:** 754.67
*   **20-Day Moving Average:** 745.97
*   **60-Day Moving Average:** 745.52

**Analysis:**

*   The current price is slightly below the 5-day moving average, indicating a short-term downtrend.  It's also very close to the 20-day and 60-day moving averages.
*   The small negative change from the previous close doesn't suggest a significant volatility event.

**3. Market Risk Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI (Relative Strength Index):** 52.57 (Neutral)
*   **PPO (Percentage Price Oscillator):** 0.063
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.41)
*   **Recent (20-day) Relative Spread Change:** -1.2 (Negative - Short-term decline)
*   **Expected Return:** 209.8% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a medium level of market risk.
*   The RSI is neutral, indicating neither overbought nor oversold conditions.
*   The negative change in the relative spread suggests some recent underperformance compared to the S&P 500.
*   The high expected return suggests strong long-term growth potential relative to the S&P 500.
*   The hybrid signal is to buy with caution.

**4. Recent News & Significant Events:**

*   **Expansion:** Eli Lilly is investing $6.5 billion in a new orforglipron production site in Texas and an API manufacturing facility.
*   **Valuation:**  Focus on how Mounjaro trial results will impact the 2025 valuation.
*   **Divestiture:** Eli Lilly is reportedly selling Imclone Systems to Celltrion for $330 million.
*   **Drug Pricing Concerns:** Eli Lilly's CEO is critical of drug pricing in the UK.

**Analysis:**

*   The significant investment in new production facilities signals confidence in future demand and growth, likely driven by drugs like orforglipron and Mounjaro.
*   The sale of Imclone Systems suggests a strategic realignment of assets.
*   Concerns about drug pricing in the UK could impact revenue in that market.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Average: $884.31, High: $1190.00, Low: $650.00
*Recent Rating Changes: No Data Provided

**Analysis:**
The strong buy consensus and the significant upside potential suggested by the average target price indicate positive sentiment from analysts. The wide range between the high and low target prices suggests some uncertainty.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-08-07 | 6.3  | 15.56 B$    |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2024-08-08 | 3.29 | 11.30 B$    |
| 2025-08-07 | 3.29 | 11.30 B$    |

**Analysis:**

*   The most recent EPS (6.3) and revenue (15.56B$) significantly outperformed previous quarters, suggesting strong growth.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $15.56B  | 84.27%        |
| 2025-03-31   | $12.73B  | 82.53%        |
| 2024-12-31   | $13.53B  | 82.24%        |
| 2024-09-30   | $11.44B  | 81.02%        |
| 2024-06-30   | $11.30B  | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2025-06-30   | $18.27B  | 30.98% |
| 2025-03-31   | $15.76B  | 17.50% |
| 2024-12-31   | $14.19B  | 31.07% |
| 2024-09-30   | $14.24B  | 6.81%  |
| 2024-06-30   | $13.56B  | 21.88% |

**Analysis:**

*   **Revenue:**  Consistent growth in revenue over the past year.
*   **Profit Margin:** Very high and increasing profit margins, indicating strong pricing power and efficient operations.
*   **Equity:** Growing equity base.
*   **ROE (Return on Equity):** ROE fluctuates but is generally high, indicating efficient use of shareholder equity to generate profits. The recent ROE is a good sign.

**7. Overall Summary:**

Eli Lilly (LLY) demonstrates a strong financial performance, outperforming the S&P 500 with a high expected return. Recent earnings and financial data show significant growth in revenue and profitability. Analyst consensus is strongly positive, with a "Buy" rating and substantial upside potential in target prices. The company is investing heavily in future growth, particularly in its pharmaceutical pipeline. However, potential challenges include drug pricing pressures and market volatility, as reflected in the MDD and MRI metrics. The recent negative change in relative spread and the slight downtrend in the stock price warrant monitoring, but the overall outlook for LLY appears positive. The strategy is to buy the stock cautiously.
